Nalorphine
From Wikipedia, the free encyclopedia
| Systematic (IUPAC) name | |
|---|---|
| (5α,6α)-17-allyl- 7,8-didehydro- 4,5-epoxymorphinan- 3,6-diol | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 62-67-9 |
| ATC code | V03AB02 |
| PubChem | CID 5284595 |
| IUPHAR ligand | 1629 |
| ChemSpider | 4447643 |
| UNII | U59WB2WRY2 |
| ChEMBL | CHEMBL415284 |
| Synonyms | (−)−(5R,6S)-9α-allyl- 4,5-epoxymorphin- 7-en- 3,6-diol |
| Chemical data | |
| Formula | C19H21NO3 |
| Mol. mass | 311.375 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| |
Nalorphine (INN, also known as N-allyl-normorphine) trade names Lethidrone and Nalline. Nalorphine acts at two opioid receptors, at the mu receptor it has antagonistic effects and at the kappa receptors it exerts agonistic characteristics. It is used to reverse opioid overdose and (starting in the 1950s) in a challenge test to determine opioid dependence.[1]
[edit] References
- ^ "Medicine: Drug Detector", Time, Dec. 24, 1956
|
| This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |

